Association of Hypoglycemic Agents with Chemotherapy Neuropathy Risk in T2D Patients

Supplementary material for a retrospective cohort study analyzing the risk of platinum-based chemotherapy-induced peripheral neuropathy in patients with type 2 diabetes. The study used a nationwide Japanese claims database from 2008 to 2022, covering 119,061 patients. The material likely contains statistical results and analysis details supporting the published findings.

Use Cases

• Validate statistical models for drug-associated neuropathy risk based on hazard ratios and confidence intervals.
• Replicate the study's methodology for analyzing claims data on chemotherapy outcomes.
• Investigate the relationship between sodium–glucose cotransporter 2 inhibitors and neurological side effects.
• Benchmark incidence rates of chemotherapy-induced peripheral neuropathy in diabetic populations.

Strengths

• Study covers a large cohort of 119,061 patients with type 2 diabetes.
• Analysis spans a 14-year period from April 2008 to December 2022.
• Outcome is defined using specific prescription and diagnostic codes.

Limitations

• Row count and column-level documentation are unknown.
• The dataset is very small (266.9 KB), suggesting it contains summary or presentation material, not the raw patient-level data.
• Data may reflect geographic bias inherent to the Japanese claims database used.

Provenance

Source

figshare admin karger

Collection Method

Retrospective cohort study using the nationwide Medical Data Vision claims database in Japan.

Time Range

April 2008 to December 2022

Freshness

Last updated 2026-04-11 07:55:15; freshness should be verified.

Geography

Japan (nationwide)